Objective: To observe the effect of immunosuppressant combined with platinum-containing chemotherapy on tumor markers and 3-year survival rate of patients with advanced non-small cell lung cancer (NSCLC). Methods: The clinical data of NSCLC patients in Xinyang Central Hospital from October 2021 to November 2023 were retrospectively selected, and 59 patients treated with platinum-based chemotherapy + sintilimab were selected as the observation group, and 59 cases were selected as the control group according to the matching principle. A total of 118 cases were selected as the samples of this study. The overall response rate (ORR), disease control rate (DCR), carbohydrate antigen 125 (CA125), cytokeratin 19 fragment antigen 21-1 (CYFRA21-1), basic fibroblast growth factor (bFGF), immune function, carcinoembryonic antigen (CEA), Karl Fischer score (KPS), vascular endothelial growth factor (VEGF), toxicity and side effects, and 3-year survival rate were compared between the two groups. Results: After treatment, the DCR and ORR in the observation group were higher than those in the control group (P＜0.05). Compared with the control group, the levels of CYFRA21-1, CEA, bFGF, CA125, and VEGF were lower in the observation group after treatment (P＜0.05). The CD4+/CD8+, CD3+, KPS score, and CD4+ levels were higher in the observation group after treatment than in the control group (P＜0.05). There was no significant difference in the toxic side effects between the two groups (P＞0.05). The survival rate in the observation group was higher than that in the control group(15.25% vs.3.39%, P＜0.05). Conclusion: Immunosuppressants combined with platinum-containing chemotherapy can inhibit the expression of tumor markers, enhance immune function, improve quality of life and improve survival in patients with advanced NSCLC.
LI Mingwei
,
XUE Jianzhang
,
PAN Na
. Observation of the efficacy of immune checkpoint inhibitors combined with chemotherapy in patients with advanced non-small cell lung cancer[J]. Journal of Baotou Medical College, 2025
, 41(8)
: 66
-70
.
DOI: 10.16833/j.cnki.jbmc.2025.08.012
[1] 吕峰, 路世鹏, 郭海华. 重组人血管内皮抑素联合吉非替尼一线治疗表皮生长因子受体突变阳性晚期非小细胞肺癌的疗效及安全性[J]. 癌症进展, 2021, 19(18): 1892-1895.
[2] 许德颖. 帕博利珠单抗联合放化疗治疗晚期非小细胞肺癌患者的临床疗效与安全性[J]. 实用药物与临床, 2022, 25(3): 232-235.
[3] Patel SA, Weiss J. Advances in the treatment of non-small cell lung cancer: immunotherapy[J]. Clin Chest Med, 2020,41(2):237-247.
[4] 周际昌. 实用肿瘤内科学[M]. 2版. 北京: 人民卫生出版社, 2003: 202-203.
[5] 杨学宁, 吴一龙. 实体瘤治疗疗效评价标准: RECIST[J]. 循证医学, 2004, 4(2): 85-90, 111.
[6] 王永, 解华, 李凌云. 贝伐珠单抗联合厄洛替尼对晚期非小细胞肺癌患者疗效、血清CYFRA21-1水平及KPS评分的影响[J]. 临床和实验医学杂志, 2021, 20(8): 827-830.
[7] Mulherkar R, Grewal AS, Berman AT. Emerging role of immunotherapy in locally advanced non-small cell lung cancer[J]. Clin Adv Hematol Oncol, 2020, 18(4): 212-217.
[8] 钟家将, 张东伟, 蓝冰, 等. 多西他赛联合顺铂治疗对中晚期非小细胞肺癌的疗效及对低剂量CT灌注成像参数的影响[J]. 中国CT和MRI杂志, 2023, 21(1): 72-73, 179.
[9] 戴丽, 王小华, 杨万春, 等. 贝伐珠单抗联合TP化疗方案对晚期非鳞癌非小细胞肺癌患者免疫功能、生活质量和血清肿瘤标志物的影响[J]. 现代生物医学进展, 2021, 21(11): 2174-2178.
[10] Liu C, Zheng S, Wang Z, et al. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer[J]. Cancer Commun (Lond), 2022, 42(9): 828-847.
[11] 林恒, 谢强. PD-1抑制剂一线治疗晚期非小细胞肺癌的疗效和安全性[J]. 中国新药与临床杂志, 2021, 40(6): 436-440.
[12] 杨艳莉, 刘红梅, 余静丽. 信迪利单抗对晚期非小细胞肺癌患者T淋巴细胞亚群的影响及其治疗效果研究[J]. 癌症进展, 2023, 21(3): 301-304, 308.
[13] 陈良新, 孙鹏, 胡中舟. 信迪利单抗联合化疗对晚期非小细胞肺癌肿瘤标志物及免疫功能的影响[J]. 检验医学与临床, 2022, 19(8): 1106-1108.
[14] 段铮, 周庆伟, 孙宏新. 化瘀散结方对晚期非小细胞肺癌患者CEA、CYFRA211、miR及MMP表达的影响[J]. 辽宁中医杂志, 2020, 47(1): 89-92.
[15] 王玲, 杜倩宇, 王西勇. 安罗替尼联合化疗治疗驱动基因阴性晚期非小细胞肺癌的疗效及对血清VEGF、bFGF、MMP-9水平的影响[J]. 临床和实验医学杂志, 2022, 21(1): 39-43.
